You are about to leave the Nuvalent website.

Nuvalent does not endorse or take responsibility for any information or statements made on external sites.

Do you wish to continue?

Cancel Continue
Nuvalent

Investor Relations

Nuvalent is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.

Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

View Corporate Presentation

Stock Information
NASDAQNUVL
Latest News & Events
Nov 14, 2023
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development...

Nov 1, 2023
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...

Oct 16, 2023
Nuvalent Announces Pricing of Public Offering of Common Stock

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the...

See All